Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 16/20 | 1.00 |
| ▸ | CA2 | P00918 | 16/20 | 1.00 |
| ▸ | CA9 | Q16790 | 16/20 | 1.00 |
| ▸ | CA12 | O43570 | 14/20 | 1.00 |
| ▸ | CA4 | P22748 | 2/20 | 1.00 |
| ▸ | CA7 | P43166 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.82 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.70 |
| ▸ | MEN1 | O00255 | 1/20 | 0.70 |
| ▸ | MAPT | P10636 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28499329 | 0.91 | KMT2A (1.00) | CA1CA2CA9CA12CA4 | |
| SCHEMBL672116 | 0.85 | CA2 (1.00) | CA1CA2CA9CA12CA4 | |
| SCHEMBL27468719 | 0.85 | CA2 (0.84) | CA1CA2CA9CA12CA4 | |
| SCHEMBL673008 | 0.85 | CA1 (1.00) | CA1CA2CA9CA12CA4 | |
| SCHEMBL672734 | 0.84 | CA2 (1.00) | CA1CA2CA9CA12CA4 | |
| SCHEMBL4554956 | 0.84 | CA2 (0.74) | CA1CA2CA9CA12CA4 | |
| SCHEMBL31310457 | 0.84 | CA1 (1.00) | CA1CA2CA9CA12CA4 | |
| SCHEMBL671546 | 0.84 | CA2 (1.00) | CA1CA2CA9CA12CA4 | |
| SCHEMBL15134184 | 0.84 | KMT2A (0.85) | CA1CA2CA9CA12CA4 | |
| SCHEMBL3070329 | 0.82 | KMT2A (0.76) | CA1CA2CA9CA12CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4637846-A1 | IMAGING REAGENTS AND METHODS | Telix Pharmaceuticals (Innovations) Pty Ltd (AU) | 2025-10-29 | — | — | EP | claimed |
| WO-2025065045-A1 | NOVEL THERAPEUTIC TARGETS | TELIX PHARMACEUTICALS (INNOVATIONS) PTY LTD (AU) | 2025-04-03 | — | — | WO | claimed |
| WO-2024130293-A1 | IMAGING REAGENTS AND METHODS | TELIX PHARMACEUTICALS (INNOVATIONS) PTY LTD (AU) | 2024-06-27 | — | — | WO | claimed |
| CN-109608371-B | O2-4- (3- (4-sulfamoylphenyl) urea) phenylazoium dialkoxide derivative, preparation method and application | 泰州学院 | 2020-12-29 | — | — | CN | claimed |
| CN-109608371-A | O2-4- (3- (4-sulfamoylphenyl) urea) phenylazoium dialkoxide derivative, preparation method and application | 泰州学院 | 2019-04-12 | — | — | CN | claimed |
| US-9962398-B2 | Sulfonamide compounds for inhibition of metastatic tumor growth | WELICHEM BIOTECH INC. (CA) | 2018-05-08 | — | — | US | claimed |
| EP-2590938-B1 | NOVEL SULFONAMIDE COMPOUNDS FOR INHIBITION OF METASTATIC TUMOR GROWTH | WELICHEM BIOTECH INC (CA) | 2017-06-07 | — | — | EP | claimed |
| US-20170007627-A1 | NOVEL SULFONAMIDE COMPOUNDS FOR INHIBITION OF METASTATIC TUMOR GROWTH | WELICHEM BIOTECH INC. (CA) | 2017-01-12 | — | — | US | claimed |
| US-20130190396-A1 | NOVEL SULFONAMIDE COMPOUNDS FOR INHIBITION OF METASTATIC TUMOR GROWTH | METASIGNAL THERAPEUTICS INC. (CA) | 2013-07-25 | — | — | US | claimed |
| EP-2590938-A1 | NOVEL SULFONAMIDE COMPOUNDS FOR INHIBITION OF METASTATIC TUMOR GROWTH | Metasignal Therapeutics Inc. (CA) | 2013-05-15 | — | — | EP | claimed |
| WO-2012021963-A1 | NOVEL SULFONAMIDE COMPOUNDS FOR INHIBITION OF METASTATIC TUMOR GROWTH | METASIGNAL THERAPEUTICS INC. (CA) | 2012-02-23 | — | — | WO | claimed |
| CN-117417465-B | Hydroxyalkyl starch compound and preparation method and application thereof | 华中科技大学 | 2026-02-27 | — | — | CN | disclosed |
| US-12522566-B2 | 2-(3-(2-methyl-6-(p-tolyl) pyridine-3-yl) ureido) benzenesulfonamide and derivatives as inhibitor of carbonic anhydrase IX for the treatment of cancer | YEDITEPE UNIVERSITESI (TR) | 2026-01-13 | — | — | US | disclosed |
| US-20260009799-A1 | CA-IX TARGETING FLUORESCENT PROBES | BRACCO IMAGING S.P.A. (IT) | 2026-01-08 | — | — | US | disclosed |
| US-20250352675-A1 | CA-IX TARGETING FLUORESCENT PROBES | BRACCO IMAGING S.P.A. (IT) | 2025-11-20 | — | — | US | disclosed |
| US-20130190396-A1 | NOVEL SULFONAMIDE COMPOUNDS FOR INHIBITION OF METASTATIC TUMOR GROWTH | METASIGNAL THERAPEUTICS INC. (CA) | 2013-07-25 | — | — | US | disclosed |
| US-20130190396-A1 | NOVEL SULFONAMIDE COMPOUNDS FOR INHIBITION OF METASTATIC TUMOR GROWTH | METASIGNAL THERAPEUTICS INC. (CA) | 2013-07-25 | — | — | US | disclosed |
| EP-2590938-A1 | NOVEL SULFONAMIDE COMPOUNDS FOR INHIBITION OF METASTATIC TUMOR GROWTH | Metasignal Therapeutics Inc. (CA) | 2013-05-15 | — | — | EP | disclosed |
| WO-2012021963-A1 | NOVEL SULFONAMIDE COMPOUNDS FOR INHIBITION OF METASTATIC TUMOR GROWTH | METASIGNAL THERAPEUTICS INC. (CA) | 2012-02-23 | — | — | WO | disclosed |
| WO-2012021963-A1 | NOVEL SULFONAMIDE COMPOUNDS FOR INHIBITION OF METASTATIC TUMOR GROWTH | METASIGNAL THERAPEUTICS INC. (CA) | 2012-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190396-A1 | NOVEL SULFONAMIDE COMPOUNDS FOR INHIBITION OF METASTATIC TUMOR GROWTH | HIF1AN, CBX2, HIF1A | CA1 31/4885CA2 5/4885CA9 25/4885 |
| US-20260009799-A1 | CA-IX TARGETING FLUORESCENT PROBES | CA9, CA12, CA1 | CA1 3/4885CA2 6/4885CA9 1/4885 |
| US-20170007627-A1 | NOVEL SULFONAMIDE COMPOUNDS FOR INHIBITION OF METASTATIC TUMOR GROWTH | HIF1AN, CBX2, HIF1A | CA1 31/4885CA2 5/4885CA9 25/4885 |
| US-20250352675-A1 | CA-IX TARGETING FLUORESCENT PROBES | CA9, CA4, CA7 | CA1 9/4885CA2 8/4885CA9 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.